• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性/复发性喉鳞状细胞癌的突变谱

Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma.

作者信息

Smith Joshua D, Birkeland Andrew C, Rosko Andrew J, Hoesli Rebecca C, Foltin Susan K, Swiecicki Paul, Mierzwa Michelle, Chinn Steven B, Shuman Andrew G, Malloy Kelly M, Casper Keith A, McLean Scott A, Wolf Gregory T, Bradford Carol R, Prince Mark E, Brenner John Chad, Spector Matthew E

机构信息

Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan.

Rogel Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan.

出版信息

Head Neck. 2019 Feb;41(2):423-428. doi: 10.1002/hed.25444. Epub 2018 Dec 12.

DOI:10.1002/hed.25444
PMID:30548484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6431792/
Abstract

BACKGROUND

We sought to describe targeted DNA sequencing data of persistent/recurrent laryngeal squamous cell carcinoma (LSCC) and to compare gene-specific alteration frequencies with that of primary, untreated LSCC specimens from The Cancer Genome Atlas (TCGA).

METHODS

The tumors of 21 patients with persistent/recurrent LSCC were subjected to targeted DNA sequencing using the Ion AmpliSeq Comprehensive Cancer Panel. Gene-specific alteration frequencies were compared (Chi-Square test) to primary, untreated LSCC sequencing data from TCGA using the cBioPortal platform.

RESULTS

Persistent/recurrent LSCC was characterized by a high rate of inactivating alterations in TP53 (38.1%) and CDKN2A (33%), amplification events of CCND1 (19.1%), and ERBB2 (14.3%), and NOTCH1 (19.1%) mutations. Comparison of primary vs persistent/recurrent LSCC revealed significant differences in alteration frequencies of eight critical genes: BAP1, CDKN2A, DCUN1D1, MSH2, MTOR, PIK3CA, TET2, and TP53.

CONCLUSIONS

Our results provide preliminary support for a distinct mutational profile of persistent/recurrent LSCC that requires validation in larger cohorts.

摘要

背景

我们试图描述持续性/复发性喉鳞状细胞癌(LSCC)的靶向DNA测序数据,并将基因特异性改变频率与来自癌症基因组图谱(TCGA)的原发性、未经治疗的LSCC标本进行比较。

方法

对21例持续性/复发性LSCC患者的肿瘤使用Ion AmpliSeq综合癌症检测板进行靶向DNA测序。使用cBioPortal平台将基因特异性改变频率与来自TCGA的原发性、未经治疗的LSCC测序数据进行比较(卡方检验)。

结果

持续性/复发性LSCC的特征在于TP53(38.1%)和CDKN2A(33%)的失活改变率高,CCND1(19.1%)、ERBB2(14.3%)的扩增事件以及NOTCH1(19.1%)突变。原发性与持续性/复发性LSCC的比较显示,八个关键基因(BAP1、CDKN2A、DCUN1D1、MSH2、MTOR、PIK3CA、TET2和TP53)的改变频率存在显著差异。

结论

我们的结果为持续性/复发性LSCC独特的突变谱提供了初步支持,这需要在更大的队列中进行验证。

相似文献

1
Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma.持续性/复发性喉鳞状细胞癌的突变谱
Head Neck. 2019 Feb;41(2):423-428. doi: 10.1002/hed.25444. Epub 2018 Dec 12.
2
HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.HOX基因:喉鳞状细胞癌进展的潜在候选因素。
Tumour Biol. 2016 Nov;37(11):15087-15096. doi: 10.1007/s13277-016-5356-8. Epub 2016 Sep 22.
3
Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma.喉鳞状细胞癌中CDK1的反复过表达。
Tumour Biol. 2016 Aug;37(8):11115-26. doi: 10.1007/s13277-016-4991-4. Epub 2016 Feb 24.
4
Establishment and characterization of a novel HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 in the DNA-binding domain.建立并鉴定了一种新型 HPV 阴性喉鳞状细胞癌细胞系 FD-LSC-1,其 DNA 结合域中存在 TP53 的错义突变和无义突变。
Cancer Lett. 2014 Jan 1;342(1):92-103. doi: 10.1016/j.canlet.2013.08.041. Epub 2013 Aug 31.
5
SLC7A11, a component of cysteine/glutamate transporter, is a novel biomarker for the diagnosis and prognosis in laryngeal squamous cell carcinoma.SLC7A11,半胱氨酸/谷氨酸转运体的一个组成部分,是喉鳞状细胞癌诊断和预后的一个新的生物标志物。
Oncol Rep. 2017 Nov;38(5):3019-3029. doi: 10.3892/or.2017.5976. Epub 2017 Sep 20.
6
Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.激肽释放酶相关肽酶4(KLK4)的低信使核糖核酸(mRNA)表达水平预示着喉鳞状细胞癌患者的短期复发。
Biol Chem. 2014 Sep;395(9):1051-62. doi: 10.1515/hsz-2014-0139.
7
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.TP53突变和S期分数而非DNA倍性是喉鳞状细胞癌的独立预后指标。
J Cell Physiol. 2006 Jan;206(1):181-8. doi: 10.1002/jcp.20447.
8
Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic laryngeal carcinoma treated with radiotherapy.磷酸化FADD对接受放疗的T1-T2声门上型喉癌的局部控制无预后价值。
Laryngoscope. 2017 Sep;127(9):E301-E307. doi: 10.1002/lary.26563. Epub 2017 Mar 17.
9
Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.喉鳞状细胞癌中CDKN2A和TP53基因的突变状态
Pathol Oncol Res. 2015 Apr;21(2):413-21. doi: 10.1007/s12253-014-9836-0. Epub 2014 Aug 23.
10
Recurrent amplification in the 22q11 region in laryngeal squamous cell carcinoma results in overexpression of the CRKL but not the MAPK1 oncogene.喉鳞状细胞癌中 22q11 区域的反复扩增导致 CRKL 的过表达,但不是 MAPK1 癌基因。
Cancer Biomark. 2010;8(1):11-9. doi: 10.3233/DMA-2011-0814.

引用本文的文献

1
The Association of , , and SNPs and Laryngeal Squamous Cell Carcinoma Development.基因多态性与喉鳞状细胞癌发展的相关性研究。
Int J Mol Sci. 2024 Nov 4;25(21):11849. doi: 10.3390/ijms252111849.
2
Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer.通过整合基因表达生物标志物实现喉癌分子谱分析的个性化治疗策略
J Pers Med. 2024 Oct 10;14(10):1048. doi: 10.3390/jpm14101048.
3
Analyzing the role of expression in pancreatic adenocarcinoma: understanding prognostic implications and therapeutic opportunities.分析表达在胰腺腺癌中的作用:了解预后意义和治疗机会。
J Gastrointest Oncol. 2024 Aug 31;15(4):1760-1776. doi: 10.21037/jgo-24-564. Epub 2024 Aug 28.
4
Berberine inhibits the malignant cell phenotype by inactivating PI3K/AKT/mTOR signaling in laryngeal squamous cell carcinoma.小檗碱通过抑制 PI3K/AKT/mTOR 信号通路抑制喉鳞状细胞癌细胞的恶性表型。
Histol Histopathol. 2024 Nov;39(11):1527-1536. doi: 10.14670/HH-18-753. Epub 2024 Apr 23.
5
Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma.多激酶补偿挽救了头颈部鳞状细胞癌细胞系模型中的 EGFR 敲除。
Arch Oral Biol. 2023 Dec;156:105822. doi: 10.1016/j.archoralbio.2023.105822. Epub 2023 Oct 11.
6
mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.突变与接受手术治疗的 T1-2N0 喉癌患者免疫应答受损和无复发生存率降低相关。
Front Immunol. 2022 Jul 15;13:920253. doi: 10.3389/fimmu.2022.920253. eCollection 2022.
7
Development and validation of a novel metabolic signature for predicting prognosis in patients with laryngeal cancer.开发并验证一种新的代谢标志物,用于预测喉癌患者的预后。
Eur Arch Otorhinolaryngol. 2021 Apr;278(4):1129-1138. doi: 10.1007/s00405-020-06444-3. Epub 2020 Oct 27.
8
Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma.氧化途径突变在复发性喉鳞状细胞癌中的预后意义
Cancers (Basel). 2020 Oct 22;12(11):3081. doi: 10.3390/cancers12113081.

本文引用的文献

1
Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project.临床全基因组测序来自常规福尔马林固定、石蜡包埋标本:10 万基因组计划的初步研究。
Genet Med. 2018 Oct;20(10):1196-1205. doi: 10.1038/gim.2017.241. Epub 2018 Feb 1.
2
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.CD4 和 CD8 肿瘤浸润淋巴细胞的比例可预测持续性/复发性喉鳞状细胞癌的生存情况。
Oral Oncol. 2018 Feb;77:83-89. doi: 10.1016/j.oraloncology.2017.12.003. Epub 2017 Dec 23.
3
BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer.BAP1 是 HPV 阴性头颈部癌症的一个新靶点。
Clin Cancer Res. 2018 Feb 1;24(3):600-607. doi: 10.1158/1078-0432.CCR-17-1573. Epub 2017 Nov 7.
4
Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.复发性/持续性喉鳞状细胞癌全喉切除术后生存的预测因素。
Head Neck. 2017 Dec;39(12):2512-2518. doi: 10.1002/hed.24918. Epub 2017 Sep 30.
5
Impact of stage, management and recurrence on survival rates in laryngeal cancer.分期、治疗及复发对喉癌生存率的影响
PLoS One. 2017 Jul 14;12(7):e0179371. doi: 10.1371/journal.pone.0179371. eCollection 2017.
6
A molecular portrait of microsatellite instability across multiple cancers.多种癌症中微卫星不稳定性的分子特征。
Nat Commun. 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180.
7
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.复发性和转移性头颈癌的分子图谱:来自精准肿瘤学测序平台的见解
JAMA Oncol. 2017 Feb 1;3(2):244-255. doi: 10.1001/jamaoncol.2016.1790.
8
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.改变模式:喉鳞状细胞癌靶向治疗的潜力
Cancer Biol Med. 2016 Mar;13(1):87-100. doi: 10.28092/j.issn.2095-3941.2016.0010.
9
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中可靶向的ERBB2异常的鉴定
JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):559-67. doi: 10.1001/jamaoto.2016.0335.
10
Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.在经靶向测序定义的流行病学低风险患者中,成纤维细胞生长因子家族异常作为头颈部鳞状细胞癌的一种假定驱动因素。
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.